HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
hC Bioscience has raised $16.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
hC Bioscience's investors include ARCH Venture Partners, 8VC, Taiho Ventures, Panacea Venture, Takeda Ventures.
hC Bioscience is headquartered in Cambridge, United States.
HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
hC Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"hC Bioscience — Funding & Investors." VCBacked, November 4, 2022, https://www.vcbacked.co/company/hc-bioscience. Accessed July 19, 2026.
VCBacked. (2022). hC Bioscience — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hc-bioscience
{{cite web |title=hC Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/hc-bioscience |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated